TCON (TRACON Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of Jan. 18, 2025)

View and export this data going back to 2015. Start your Free Trial

What is TRACON Pharmaceuticals Forward Dividend Yield %?

As of today (2025-01-18), the Forward Annual Dividend Yield of TRACON Pharmaceuticals is 0.00%.

As of today (2025-01-18), the Trailing Annual Dividend Yield of TRACON Pharmaceuticals is 0.00%.

TCON's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.58
* Ranked among companies with meaningful Forward Dividend Yield % only.

TRACON Pharmaceuticals's Dividends per Share for the three months ended in Jun. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of TRACON Pharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, TRACON Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TRACON Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TRACON Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where TRACON Pharmaceuticals's Forward Dividend Yield % falls into.

TRACON Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

TRACON Pharmaceuticals (OTCPK:TCON) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

TRACON Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of TRACON Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

TRACON Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TRACON Pharmaceuticals Inc (OTCPK:TCON) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA, 92122

Website

https://www.traconpharma.com

TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.

Executives

Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Charles Theuer	director, officer: President and CEO	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Bonne J. Adams	officer: Chief Operating Officer	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Scott B. Brown	officer: Chief Accounting Officer (PAO)	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
William R Larue	director	C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, SUITE 700, SAN DIEGO CA 92122
Carol C. Lam	director	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, STE 800, SAN DIEGO CA 92122
Saundra L Pelletier	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Johnson-pratt	director	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Ikarian Healthcare Master Fund, L.p.	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Mark C Wiggins	officer: Chief Business Officer	12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Neil Shahrestani	10 percent owner, other: Member of 10% Group	12806 WINDING CREEK DRIVE, FRISCO TX 75035
Ikarian Healthcare Fund Gp, L.p.	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Chart Westcott Living Trust	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Ikarian Capital, Llc	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Puissance Cross-border Opportunities V Llc	10 percent owner	950 THIRD AVENUE, 25TH FL, NEW YORK NY 10022